印度正在成为全球医疗保健领导者, 在2024年至25年间将出口305亿美元的药物和疫苗. India is rising as a global healthcare leader, exporting $30.5B in medicines and vaccines in 2024–25, driven by innovation and self-reliance.

印度正在迅速成为制药和医疗技术的全球领导者, 从进口依赖转向自主创新和高质量生产. India is rapidly advancing as a global leader in pharmaceuticals and medical technology, transitioning from import dependence to self-reliance through indigenous innovation and high-quality manufacturing. 现在这个行业是全球最大的仿制药供应商和疫苗的主要提供者, 到2024年到25年出口量将达到305亿美元,国内市场预计在2030年前增长至1300亿美元. The sector, now the world’s largest supplier of generic medicines and a key provider of vaccines, has seen exports reach $30.5 billion in 2024–25, with a domestic market projected to grow to $130 billion by 2030. 政府的举措,如PRIP计划和2023年国家医疗器械政策正在推动创新,扩大印度在全球医疗设备市场占有率的1.5%,并支持向高价值生产转变. Government initiatives like the PRIP scheme and the National Medical Device Policy 2023 are driving innovation, expanding India’s 1.5% share of the global medical devices market, and supporting a shift toward high-value production. 印度在国内抗生素,疫苗和医疗器械开发方面取得的成功 - 其中许多符合国际标准 - 使其作为可靠的全球卫生保健合作伙伴的作用得到加强,特别是在大流行期间. India’s success in developing homegrown antibiotics, vaccines, and medical devices—many meeting international standards—has strengthened its role as a reliable global healthcare partner, particularly during the pandemic.